Compare ROL & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ROL | UTHR |
|---|---|---|
| Founded | 1948 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.5B | 23.9B |
| IPO Year | 1994 | 1999 |
| Metric | ROL | UTHR |
|---|---|---|
| Price | $52.54 | $522.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 14 |
| Target Price | $66.10 | ★ $533.21 |
| AVG Volume (30 Days) | ★ 2.4M | 515.9K |
| Earning Date | 04-22-2026 | 04-29-2026 |
| Dividend Yield | ★ 1.38% | N/A |
| EPS Growth | ★ 13.54 | 13.07 |
| EPS | 1.09 | ★ 27.86 |
| Revenue | ★ $2,161,220,000.00 | $1,483,300,000.00 |
| Revenue This Year | $10.42 | $7.05 |
| Revenue Next Year | $8.81 | $13.30 |
| P/E Ratio | $48.51 | ★ $19.10 |
| Revenue Growth | ★ 7.23 | 2.38 |
| 52 Week Low | $51.77 | $266.98 |
| 52 Week High | $66.14 | $549.50 |
| Indicator | ROL | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 26.74 | 51.98 |
| Support Level | N/A | $464.92 |
| Resistance Level | $58.38 | $542.66 |
| Average True Range (ATR) | 1.21 | 13.01 |
| MACD | -0.14 | -1.45 |
| Stochastic Oscillator | 4.13 | 11.73 |
Rollins is a global leader in route-based pest control services, with operations primarily in the United States and across North, Central, and South America, Europe, the Middle East, Africa, and Australia. Its portfolio of pest-control brands includes the prominent Orkin brand, a market leader in the US and Canada, with near-national coverage. It also has a portfolio of other brands, which it uses to reach customers through alternative sales channels. Residential pest and termite prevention accounts for the majority of Rollins' services, reflecting its ongoing focus on the US and Canadian markets.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.